Whistler Conference Centre Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2007



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Molecular Targets for Cancer (X3)


Organizer(s) William G. Kaelin Jr. and Sara A. Courtneidge
March 18—23, 2007
Whistler Conference Centre • Whistler, British Columbia Canada
Abstract Deadline: Nov 20, 2006
Late Abstract Deadline: Dec 19, 2006
Scholarship Deadline: Nov 20, 2006
Early Registration Deadline: Jan 18, 2007

Part of the Translational Medicine Series, Sponsored by Pfizer Global Research & Development


Summary of Meeting:
The molecular circuits that are altered in cancers and responsible for malignant transformation are coming into better focus. In some cases cancer cells become ‘addicted’ to these abnormal circuits (networks). Discoveries related to cancer-relevant mutations, and the dependencies they create, will likely accelerate due to cancer resequencing efforts and phenotypic screens with genome-wide si/shRNA libraries. The success of imatinib for both chronic myelogenous leukemia and gastrointestinal stromal tumor and of gefitinib for lung cancers driven by mutant EGFR confirms that drugs targeting oncoproteins can induce tumor regressions with acceptable toxicity. Because of this, a number of agents that inhibit receptor tyrosine kinases, as well as downstream signaling molecules such as those in the Ras-Raf pathway and PI3K-AKT-mTOR pathway, are now being developed. The validity of preclinical models, and the need for robust pharmacodynamic assays, remains a challenge. This meeting will bring together experts and trainees to discuss these challenges in the context of present and future cancer drug targets.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


SUNDAY, MARCH 18

15:00—19:30
Registration

Foyer
18:30—19:30
Refreshments

Foyer
19:30—21:30
Keynote Session (Joint)
Meeting has ended...abstracts no longer viewable online.

Sky Ballroom B/C
Hans C. Clevers, Hubrecht Institute, Netherlands
Wnt and Notch Cooperate to Maintain Proliferative Compartments in Crypts and Intestinal Neoplasma

Gerard I. Evan, University of Cambridge, UK
Oncogenes and Tumor Suppressors: The Good, the Bad, and the Ugly


MONDAY, MARCH 19

07:00—08:00
Breakfast

Ballroom C/Foyer
08:00—11:00
Receptor Tyrosine Kinases
Meeting has ended...abstracts no longer viewable online.

Ballroom A
Jeffrey Settleman, Calico Life Sciences, USA
’Addiction’ to Oncogenic Kinases in Human Cancer

Samuel A. Wells, Duke University, USA
Small Molecule Targeted Therapy with Vandetanib in Patients with Metastatic Hereditary Medullary Thyroid Carcinoma

Paolo M. Comoglio, University of Torino Medical School, Italy
The MET Oncogene: Targeting Invasive Growth in Cancer and Stem Cells

Poul H. B. Sorensen, University of British Columbia, Canada
Short Talk: The ETV6-NTRK3 Oncogenic Tyrosine Kinase Directly Activates the Insulin-Like Growth Factor 1 Receptor (IGF-IR): Implications for Targeting IGF-IR in Human Tumors

John Hood, Wintherix, LLC, USA
Short Talk: TG101348, a Potent, Highly Selective JAK2 Inhibitor, Inhibits Colony Formation in Stem Cells from Polycythemia Vera Patients in Vitro & Prevents JAK2V617F-Mediated Splenomegaly and Death in an in Vivo Mouse Model

08:00—11:00
Cancer Pathways: Function and Mechanism
Meeting has ended...abstracts no longer viewable online.

Ballroom B
Scott W. Lowe, Memorial Sloan Kettering Cancer Center, USA
Dissecting Tumor Suppressor Gene Networks in vivo

Andrew Koff, Memorial Sloan-Kettering Cancer Center, USA
Short Talk: An Oncogenic Role for the Cdk Inhibitor p21Waf1/Cip1 in Gliomagenesis

* Jacqueline A. Lees, Massachusetts Institute of Technology, USA
E2F Transcription Factors in Cancer Regulation

Guillermina Lozano, University of Texas MD Anderson Cancer Center, USA
The p53 Pathways in Tumor Suppression

Christopher J. Kemp, Fred Hutchinson Cancer Research Center, USA
Short Talk: Rescue of the Apoptosis Defect of p53 Null Cells by Mutation of Ku70, Ku80, or DNA-PKcs

09:20—09:40
Coffee Break

Foyer
11:00—13:00
Poster Setup

Ballroom C/Foyer
13:00—22:00
Poster Viewing

Ballroom C/Foyer
16:30—17:00
Coffee Available

Foyer
17:00—19:00
PI3K/AKT/mTOR Pathway
Meeting has ended...abstracts no longer viewable online.

Ballroom A
Robert T. Abraham, Pfizer Worldwide Research and Development, USA
The mTOR Signaling Pathway: Linking Basic Biology to Cancer Therapy

David J. Matthews, Exelixis Inc., USA
Targeting Aberrant PI-3 Kinase Signaling in Cancer

William A. Weiss, University of California, San Francisco, USA
Cooperative Inhibition of EGFR, PI3K alpha, and mTOR in PTEN-Mutant Glioma

17:00—19:00
Cancer Pathways: Discovery Strategies
Meeting has ended...abstracts no longer viewable online.

Ballroom B
* Gerard I. Evan, University of Cambridge, UK

Nancy A. Jenkins, Institute of Molecular and Cell Biology, Singapore
Insertional Mutagenesis Provides a Road Map for Characterizing the Cancer Genome

Lynda Chin, University of Texas MD Anderson Cancer Center, USA
Oncogenomic analyses of mouse and human tumors

Lara Shayne Collier, University of Minnesota, USA
Short Talk: Cancer Gene Discovery using the Sleeping Beauty Transposon System

Anton J. M. Berns, Netherlands Cancer Institute, Netherlands
Mouse Models for Cancer

19:00—20:00
Social Hour with Lite Bites

Ballroom C/Foyer
19:30—22:00
Poster Session 1

Ballroom C/Foyer

TUESDAY, MARCH 20

07:00—08:00
Breakfast

Ballroom C/Foyer
08:00—10:20
Ras/Raf/MAPK Pathway
Meeting has ended...abstracts no longer viewable online.

Ballroom A
Julian H. Downward, Cancer Research UK, UK
Ras Oncogene Signaling Networks

Patrick J. Casey, Duke University Medical Center, USA
Targeting Proliferation and Survival Pathways with Isoprenylcysteine Carboxymethyltransferase Inhibitors

Judith Sebolt-Leopold, , USA
Development of MEK Inhibitors – A Selective Approach to Targeting the Ras–MAP Kinase Pathway

08:00—11:00
Genetic Instability and Cancer Evolution
Meeting has ended...abstracts no longer viewable online.

Ballroom B
* Joanna L. Groden, Ohio State University, USA
Chromosome Instability and Cancer

Catherine T. Yan, CBR Institute for Biomedical Research, USA
NHEJ and the Double-Strand Break Response in IgH Class Switch Recombination and Suppression of Translocations and Lymphoma

Erik S. Knudsen, UT Southwestern, USA
Short Talk: RB Loss Promotes Liver Tumorigenesis by Compromising Genome Integrity

Alan Ashworth, Institute of Cancer Research, UK
Exploiting DNA Repair Defects in Tumors as a Therapeutic Strategy

Steven E. Artandi, Stanford University, USA
Short Talk: Regulation of Tissue Stem Cells by TERT

Sandy Chang, University of Texas MD Anderson Cancer Center, USA
Telomer End Protection in Senescence and Cancer

Philipp Kaldis, Institute of Molecular and Cell Biology, Singapore
Short Talk: Mouse Models to Investigate Cell Cycle and DNA Damage

10:20—11:00
BCR-ABL and Lympholeukemia
Meeting has ended...abstracts no longer viewable online.

Ballroom A
Charles J. Sherr, St. Jude Children's Research Hospital, USA
Combating Non-Tumor-Cell-Autonomous Imatinib Resistance in Ph+ ALL

09:20—09:40
Coffee Break

Foyer
11:00—13:00
Poster Setup

Ballroom C/Foyer
13:00—22:00
Poster Viewing

Ballroom C/Foyer
16:30—17:00
Coffee Available

Foyer
17:00—19:00
Protein Folding/Ubiquitination
Meeting has ended...abstracts no longer viewable online.

Ballroom A
Neal Rosen, Memorial Sloan-Kettering Cancer Center, USA
Development of HSP90 Inhibitors for Cancer

Michael Tyers, University of Montreal, Canada
Pleonastic Phosphorylation, Substrate Recognition and Higher Order Structure of the SCF Ubiquitin Ligase

Mark K. Bennett, Calithera Biosciences, USA
Development of Epoxyketone-based Proteasome Inhibitors

17:00—19:00
Regulation and Cancer Evolution
Meeting has ended...abstracts no longer viewable online.

Ballroom B
Martin McMahon, University of California, San Francisco, USA
Tumorigenesis and Senescence Induction by Oncogenic BRafv600E in vivo

Tavanna Buske, , USA
Short Talk: A Hypomorphic Mutation in DNA Replication Gene Mcm4 Confers Mammary Specific Tumorigenesis in Mice

Andrew Xiao, Yale University, USA
Short Talk: The WSTF-SNF2H Complex Regulates the H2A.X DNA Damage Response

Al Charest, Tufts-NEMC, Massachusetts Institute of Technology, USA
Short Talk: Therapeutic Applicability of Nanoparticle-Mediated Delivery of siRNA in a Mouse Model of Glioblastoma Multiforme

* Hong Wu, UCLA/IMED c/o Cyndi Haddad, USA
PTEN, Stem Cells and Tumorigenesis

19:00—20:00
Social Hour with Lite Bites

Ballroom C/Foyer
19:30—22:00
Poster Session 2

Ballroom C/Foyer

WEDNESDAY, MARCH 21

07:00—08:00
Breakfast

Ballroom C/Foyer
08:00—11:00
Angiogenesis
Meeting has ended...abstracts no longer viewable online.

Ballroom A
Eli Keshet, Hebrew University, Israel
Lessons from Preclinical Models of VEGF-Dependent Angiogenesis

Luisa Iruela-Arispe, University of California, Los Angeles, USA
Microenvironmental Signals and Angiogenesis

Jacques Pouysségur, University of Nice, France
Hypoxia Signaling and Cancer - Targeting Angiogenesis and Tumor Metabolism

Roy Bicknell, University of Birmingham, UK
Novel Anti-Cancer Targets in the Vasculature

08:00—11:00
The Experimental Mouse in Preclinical Discovery
Meeting has ended...abstracts no longer viewable online.

Ballroom B
Kwok-Kin Wong, Dana-Farber Cancer Institute, USA
The Use of Mouse Lung Cancer Models for Preclinical Testing of Novel Targeted Therapeutics

Ross A. Dickins, Walter & Eliza Hall Institute, Australia
Short Talk: Tissue-Specific and Reversible RNAi in Transgenic Mice

Samir Hanash, Fred Hutchinson Cancer Research Center, USA
Cancer Biomarker Discovery Using Mouse Models

* Douglas Hanahan, ISREC, Switzerland
Assessing Mechanism-based Cancer Therapeutics in Engineered Mouse Models of Cancer: Targeting EGFR and mTOR

Trevor J. Hay, Cardiff University, UK
Short Talk: Regression of Brca2-/- p53-/- Mouse Mammary Tumours by PARP Inhibition

Loren D. Walensky, Dana-Farber Cancer Institute, USA
Piloting “BH3 Replacement” Therapy in Murine Models of Deregulated Apoptosis

09:20—09:40
Coffee Break

Foyer
11:00—13:00
Poster Setup

Ballroom C/Foyer
13:00—22:00
Poster Viewing

Ballroom C/Foyer
16:30—17:00
Coffee Available

Foyer
17:00—19:00
Stem Cell Pathways
Meeting has ended...abstracts no longer viewable online.

Ballroom A
Stuart H. Orkin, Dana-Farber Cancer Institute, USA
Modeling Human Cancer in the Mouse to Identify Relevant Pathways for Transformation or Progression

A. Thomas Look, Dana-Farber Cancer Institute, USA
Gamma Secretase Inhibitors and Notch

Frederic J. de Sauvage, Genentech, Inc., USA
Hedgehog Pathway and Cancer

17:00—19:00
The Mouse in Translation: Highlight on Challenges
Meeting has ended...abstracts no longer viewable online.

Ballroom B
* Anton J. M. Berns, Netherlands Cancer Institute, Netherlands

David W. Threadgill, University of North Carolina at Chapel Hill, USA
Complexities fo EGFR Signaling in Cancer

Martine F. Roussel, St. Jude Children's Research Hospital, USA
Molecular Determinations of Medulloblastoma

Elaine V. Fuchs, HHMI/Rockefeller University, USA
Mouse Models of Cancer through Default of Focusing on Skin Morphogenesis

19:00—20:00
Social Hour with Lite Bites

Ballroom C/Foyer
19:30—22:00
Poster Session 3

Ballroom C/Foyer

THURSDAY, MARCH 22

07:00—08:00
Breakfast

Ballroom C/Foyer
08:00—11:00
New Technologies for Target Discovery
Meeting has ended...abstracts no longer viewable online.

Ballroom A
Michael Stratton, Wellcome Trust Sanger Institute, UK
Patterns of Somatic Mutation in Human Cancer Genomes

Matthias Mann, Max Planck Institute of Biochemistry, Germany
Global, Site Specific and Quantitative Phosphoproteomics for Drug Discovery

Gordon B. Mills, University of Texas MD Anderson Cancer Center, USA
Protein Microarrays

Roderick L. Beijersbergen, Netherlands Cancer Institute, Netherlands
Identification of Novel Drug Targets through Loss of Function Genetic Screens

08:00—11:00
Cancer Microenvironment
Meeting has ended...abstracts no longer viewable online.

Ballroom B
Robert Benezra, Memorial Sloan-Kettering Cancer Center, USA
The Role of Id Proteins in Tumor Angiogenesis

Sandra S. McAllister, Brigham & Women's Hospital/Harvard Medical School, USA
Short Talk: Systemic Instigation of Indolent Tumor Growth by Distant Primary Tumors via Activation of Sca1+ Bone Marrow Cells

* Lisa M. Coussens, Oregon Health & Science University, USA
Inflammation, Humoral Immunity and Epithelial Cancer Development

Harold L. Moses, Vanderbilt University, USA
Stromal and Epithelial TGF-beta Signaling in Carcinoma Initiation and Progression

Victor D. Acevedo, Memorial Sloan Kettering, USA
Short Talk: Conditional Activation of FGF Receptor-1 Leads to an Irreversible Prostate Adenocarcinoma and Allows for an Epithelial to Mesenchymal Transition

Joan Massagué, Memorial Sloan Kettering Cancer Center, USA
TGFbeta Signaling: From Cytostasis to Metastasis

09:20—09:40
Coffee Break

Foyer
16:30—17:00
Coffee Available

Foyer
17:00—19:00
Modulating Gene Expression
Meeting has ended...abstracts no longer viewable online.

Ballroom A
Kapil N. Bhalla, Houston Methodist Hospital Research Institute, USA
HDACs as Therapeutic Targets

Todd R. Golub, Broad Institute, USA
Modulating Gene Expression Signatures with Small Molecules

Robert J. Klose, University of Oxford, UK
Histone Demethylases as Potential Therapeutic Targets in Cancer

17:00—19:00
Stem Cells and Cancer Stem Cells: The Beginning at the End
Meeting has ended...abstracts no longer viewable online.

Ballroom B
* Jeffrey M. Rosen, Baylor College of Medicine, USA
Stem/Progenitor Cells in the Etiology and Treatment of Breast Cancer

Emmanuelle Passegué, Columbia University, USA
Cancer Stem Cells and Development of Blood Cancers

Robert I. Glazer, Georgetown University, USA
Short Talk: Peroxisome Proliferator-Activated Receptor-gamma is a Regulator of Mammary Stem and Progenitor Cell Self-Renewal and Estrogen-Dependent Tumor Specification

Maarten Van Lohuizen, Netherlands Cancer Institute, Netherlands
Polycomb Repressors Controlling Stem Cell Fate: Implications for Cancer and Development

20:00—21:00
Social Hour with Lite Bites

Ballroom C/Foyer
21:00—00:00
Entertainment

Ballroom C

FRIDAY, MARCH 23

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1 R13 CA124284-01




We gratefully acknowledge additional support for this conference from:

Ariadne Genomics Cell Signaling Technology, Inc.
Educational donation provided by Amgen Educational grant from Millennium Pharmaceuticals, Inc., The Takeda Oncology Company
EntreMed, Inc. Integrated DNA Technologies
Invitrogen Corporation Pfizer Global Research & Development
Teva Pharmaceutical Industries Ltd.
 

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Pfizer Global Research & Development


Proteolix, Inc.


Wyeth Pharmaceuticals


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676